Recombinant Human CD39L1 (C-6His)

Description

EnkiLife provides the Recombinant Human CD39L1 (C-6His) protein,aslo know as Ectonucleoside triphosphate diphosphohydrolase 2,Entpd2, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Ecto-Nucleoside Triphosphate Diphosphohydrolase 2 is produced by our Mammalian expression system and the target gene encoding Thr29-Asp460 is expressedwith a 6His tag at the C-terminus.Accession:Q9Y5L3. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:48 KDa. Background:CD39L1 protein (ENTPD2 or NTPDase2) is a member of the ecto-nucleoside triphosphate diphosphohydrolase family which the main role is termination of purinergic signaling. CD39L1 gene encodes a precursor protein with 495 amino acid residues which generates a 437 amino acid residues mature protein after processing. It is an ecto-nucleotidase that found on the surface of vascular adventitial cells and accessory vascular cells. CD39L1 is a Ca2+- and Mg2+-dependent enzyme that activates platelets by preferentially converting ATP to ADP. CD39L1 plays a role in regulating thrombosis and inflammation which is considered to be a therapeutic target for thromboregulation and the treatment of vascular inflammation. Alternative splicing of CD39L1 gene results in multiple transcript variants.